Spots Global Cancer Trial Database for A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
Official Title: A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
Study ID: NCT00431873
Conditions
Interventions
Study Description
Brief Summary: In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with refractory chronic lymphocytic leukemia.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Veteran Affairs Medical Center Research Service, Kansas City, Missouri, United States
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Gabrail Cancer Center, Canton, Ohio, United States
Cleveland Clinic/Chronic Leukemia/Multiple Myeloma Program, Cleveland, Ohio, United States
Ohio State University, James Cancer Hospital, Colombus, Ohio, United States
MD Anderson Cancer Center, Houston, Texas, United States
Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
McMaster University Health Center, Hamilton, Ontario, Canada
Ottawa Hospital - General Campus, Ottawa, Ontario, Canada
UHN - Princess Margaret Hospital, Toronto, Ontario, Canada
Hopital Charles-LeMoyne, Greenfield Park, Quebec, Canada
Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada
CHA, Hopital Enfant-Jesus, Quebec, , Canada
Contact Details
Name: Gregory Reid, MSc, MBA
Affiliation: MethylGene Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
